Presented by
Philip Stephens

Nominated by
Fraunhofer Institute for Interfacial Engineering and Biotechnology

 

Noscendo is providing diagnostic services to intensive care clinicians to efficiently treat patients suffering from infectious diseases. Using next generation sequencing methods of cell free DNA, their technology identifies pathogens in patient’s plasma samples.

Focusing on sepsis, Noscendo delivers highly sensitive and specific identifications of bacteria, viruses, fungi and parasites in one assay. By reading out free floating DNA in the patient’s blood stream, the microbes in the blood stream of patients are identified and their relevance assessed. This data enables clinicians to specifically tailor the treatment towards the most relevant microbes causing the sepsis. By rendering a timely and precise diagnosis possible, Noscendo’s novel technology raises the chances of survival and minimises the risks of complications for patients. In addition, the fact that doctors are enabled to make informed treatment decisions helps to avoid the use of broad spectra antibiotics and thus fights the existence of multi-resistant microbes.

While existing solutions in the area of sepsis diagnostics deliver qualitative yes/no answers, Noscendo brings quantitative, more sensitive and highly specific diagnostic results. This way, doctors can find the appropriate treatment and render therapy more effective and efficient.

More Venture Finalists

All Venture Finalists